Screener
Anika Therapeutics ANIK Net Income
Discontinued — last reported Q2 '26
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Anika Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Anika Therapeutics’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001171843-26-005012
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Provision for income taxes | 71 | 681 | 306 | 770 |
| Income (loss) from continuing operations | 3,309 | (4,647) | (1,747) | (8,605) |
| Income (loss) from discontinued operations, net of tax | - | 677 | - | (238) |
| Net income (loss) | $3,309 | $(3,970) | $(1,747) | $(8,843) |
| Income (loss) per share: | ||||
| Basic | ||||
| Continuing operations | $0.25 | $(0.33) | $(0.13) | $(0.60) |
| Discontinued operations | - | 0.05 | - | (0.02) |
ITEM 1. FINANCIAL STATEMENTS[ Item 1. Condensed Consolidated Financial Statements (unaudited): ](#)
FAQ
- What is Anika Therapeutics's net income?
- Anika Therapeutics (ANIK) reported net income of $3.31M in Q2 2026.
- How has Anika Therapeutics's net income changed year-over-year?
- Anika Therapeutics's net income increased by 183.4% year-over-year, from -$3.97M to $3.31M.
- What is the long-term trend for Anika Therapeutics's net income?
- Over 3 years (2022 to 2025), Anika Therapeutics's net income has grown at a -9.1% compound annual growth rate (CAGR), from -$14.86M to -$11.17M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Anika Therapeutics's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude